Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the ...

Eli Lilly is a safer way to capitalize on AI-driven drug discovery.

I have written a function to calculate the Runge-Kutta numerical approximation of the differential equation dy/dt = -2ty^2 w/ initial conditions y(0)=1 from t=0 to t=10. The function worked when I ...

Despite near-significant Phase 2 data, Recursion's lead drug REC-994 for CCM remains unconvincing as a validation of their AI platform, being a repurposed compound. Pipeline expansion in oncology ...

Recursion Pharmaceuticals has an innovative, AI-focused approach to developing drugs. However, the company has yet to find tangible success and faces several headwinds. The stock has substantial ...